Received Feb 14, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | — | — |
severe weakness; Anxiety; she experienced increased blood pressure; pressure in her head; itching on her left arm and left leg; This non-serious case was reported by a consumer via call center representative and described the occurrence of weakness in a 50-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. In FEB-2025, the patient received the 1st dose of Shingrix. In FEB-2025, an unknown time after receiving Shingrix, the patient experienced weakness (Verbatim: severe weakness), anxiety (Verbatim: Anxiety), increased blood pressure (Verbatim: she experienced increased blood pressure), head pressure (Verbatim: pressure in her head) and pruritus (Verbatim: itching on her left arm and left leg). The outcome of the weakness, anxiety, increased blood pressure, head pressure and pruritus were unknown. It was unknown if the reporter considered the weakness, anxiety, increased blood pressure, head pressure and pruritus to be related to Shingrix. It was unknown if the company considered the weakness, anxiety, increased blood pressure, head pressure and pruritus to be related to Shingrix. Additional Information: GSK Receipt Date: 07-FEB-2025 The patient who received her first dose of Shingrix vaccine 2 days prior to the reporting date and after the dose, she experienced increased blood pressure, anxiety, itching on her left arm and left leg, pressure in her head and severe weakness.
Test Date: 202502; Test Name: blood pressure; Result Unstructured Data: (Test Result:increased,Unit:unknown,Normal Low:,Normal High:) Blood pressure increased